| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
SMOKING |
1 P3 Research, Wellington, New Zealand
2 Wellington School of Medicine and Health Sciences, Wellington, New Zealand
3 Medical Research Institute of New Zealand, Wellington, New Zealand and University of Southampton, Southampton, UK
Correspondence to:
Correspondence to:
Dr S Holt
P3 Research, Bowen Hospital, Churchill Drive, Crofton Downs, Wellington, New Zealand; shaun{at}p3research.co.nz
Background: Smoking rates are high in indigenous populations and contribute to their poor health. In New Zealand the indigenous Maori population has a high rate of smoking, with around 50% of adults being smokers compared with 20% of the adult European population. A study was undertaken to determine whether bupropion is effective in the treatment of smoking cessation in the indigenous Maori population in New Zealand.
Methods: A randomised, placebo controlled, double blind, parallel group study was performed in 134 Maori smokers aged 16–70 years who smoked more than 10 cigarettes per day. The main outcome measures were continued abstinence from smoking at 3 and 12 months.
Results: At each time point continued abstinence was better for the subjects allocated to bupropion, with a risk ratio for abstinence over all time points of 2.44 (95% CI 1.22 to 4.88). The rates of continued abstinence in the bupropion and placebo groups at 3 months were 44.3% and 17.4%, respectively, with a risk ratio of 2.54 (95% CI 1.30 to 5.00). The corresponding figures at 12 months were 21.6% and 10.9%, respectively, with a risk ratio of 1.99 (95% CI 0.79 to 5.00).
Conclusion: Bupropion is an effective treatment for smoking cessation in the indigenous Maori population in New Zealand.
Keywords: smoking cessation; bupropion; Maori
This article has been cited by other articles:
|
|
 |
|
  M. J. Eisenberg MD MPH, K. B. Filion MSc, D. Yavin BSc, P. Belisle MSc, S. Mottillo BSc, L. Joseph PhD, A. Gervais MD, J. O'Loughlin PhD, G. Paradis MD MSc, S. Rinfret MD MSc, et al. Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials Can. Med. Assoc. J., July 15, 2008; 179(2): 135 - 144. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. R.N. Else, E. S. Hishinuma, D. A. Goebert, S. T. Nishimura, and S. Baker Predicting Cigarette Use Among Hawai`i Adolescents School Psychology International, May 1, 2008; 29(2): 230 - 247. [Abstract] [PDF]
|
|
|
|
 |
|
 L. Ranney, C. Melvin, L. Lux, E. McClain, and K. N. Lohr Systematic Review: Smoking Cessation Intervention Strategies for Adults and Adults in Special Populations Ann Intern Med, December 5, 2006; 145(11): 845 - 856. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Minerva BMJ, February 19, 2005; 330(7488): 428 - 428. [Full Text] [PDF]
|
|
Read all eLetters
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
